GANAB — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2268716	0.86	3/20
SCHEMBL14020226	0.86	3/20
SCHEMBL14020234	0.86	3/20
SCHEMBL25748644	0.86	3/20
Hydrochloric Acid (SCHEMBL14976072)	0.83	3/20
SCHEMBL15599045	0.69	3/20
SCHEMBL18730394	0.69	3/20
SCHEMBL5576144	0.60	3/20
SCHEMBL22693206	0.57	3/20
SCHEMBL8892109	0.54	3/20
Pyrrolidine (SCHEMBL3430488)	0.50	3/20
SCHEMBL11193060	1.00	2/20
SCHEMBL11193067	1.00	2/20
SCHEMBL15599039	1.00	2/20
SCHEMBL29471360	1.00	2/20
SCHEMBL8170837	0.88	2/20
SCHEMBL8170879	0.88	2/20
SCHEMBL8170898	0.88	2/20
SCHEMBL8171453	0.88	2/20
SCHEMBL8171977	0.88	2/20

Clinical trials — most relevant to GANAB by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease	PHASE4	COMPLETED
Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment	PHASE4	COMPLETED
China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD	PHASE4	RECRUITING
Evaluation of Fenugreek Seed Extract In Type- 2 Diabetes: An Add-On Study	PHASE4	COMPLETED
Early Diabetes Intervention Program	PHASE4	COMPLETED
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease	PHASE4	COMPLETED
A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease	PHASE3	COMPLETED
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease	PHASE3	COMPLETED
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)	PHASE3	COMPLETED
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa	PHASE3	ACTIVE_NOT_RECRUITING
Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3	PHASE3	COMPLETED
Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease	PHASE3	COMPLETED
Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan	PHASE2/PHASE3	COMPLETED
Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase	PHASE2/PHASE3	COMPLETED
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants	PHASE3	RECRUITING
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients	PHASE3	COMPLETED
OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease	PHASE2	COMPLETED
A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa	PHASE2	ACTIVE_NOT_RECRUITING
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension	PHASE2	ACTIVE_NOT_RECRUITING
Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)	PHASE1/PHASE2	COMPLETED
Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease	PHASE2	COMPLETED
Glycemic Response of Whole Beans and Bean Products	EARLY_PHASE1	COMPLETED
Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months (STIG-Pompe-Study)	nan	COMPLETED
Newborn Screening Assay of Pompe's Disease	nan	COMPLETED
Assessment of Neurological Manifestations in Gaucher Disease Patients	nan	UNKNOWN
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease	nan	COMPLETED
A Long Term Follow up Study in Late-onset Pompe Disease	nan	UNKNOWN
Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease	nan	APPROVED_FOR_MARKETING
A Prospective, Observational Study in Patients With Late-Onset Pompe Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GANAB binder may also engage these)

Protein	Name	Similarity
P79403	—	1.000	P79403 →
Q4R4N7	—	1.000	Q4R4N7 →
Q8BHN3	—	1.000	Q8BHN3 →
GAA	Lysosomal alpha-glucosidase	0.992	landscape →
P70699	—	0.991	P70699 →
Q9MYM4	—	0.987	Q9MYM4 →
Q5R7A9	—	0.986	Q5R7A9 →
Q6P7A9	—	0.985	Q6P7A9 →
Q9BE70	—	0.981	Q9BE70 →
Q8BVW0	—	0.980	Q8BVW0 →
O97524	—	0.979	O97524 →
Q69ZQ1	—	0.978	Q69ZQ1 →
O46432	—	0.978	O46432 →
B9F676	—	0.977	B9F676 →
Q8K2I4	—	0.977	Q8K2I4 →
O18835	—	0.977	O18835 →
Q5R5N6	—	0.977	Q5R5N6 →
GANC	Neutral alpha-glucosidase C	0.977	landscape →
Q4FAT7	—	0.976	Q4FAT7 →
Q8VHC8	—	0.976	Q8VHC8 →
P17164	—	0.976	P17164 →
FUCA1	Tissue alpha-L-fucosidase	0.975	landscape →
O77695	—	0.975	O77695 →
Q60HF8	—	0.975	Q60HF8 →
Q3U4H6	—	0.975	Q3U4H6 →
Q9FN05	—	0.974	Q9FN05 →
Q6NSJ0	—	0.973	Q6NSJ0 →
Q99KR8	—	0.973	Q99KR8 →
Q2KIM0	—	0.973	Q2KIM0 →
FUCA2	Plasma alpha-L-fucosidase	0.973	landscape →